Loading
BP
Bellicum Pharmaceuticals, Inc Stock: price and insider trades · United States
Bellicum Pharmaceuticals, Inc: what insiders have been doing
Bellicum Pharmaceuticals, Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Bellicum Pharmaceuticals, Inc has had no insider filing for more than a year; the last one goes back to 24 November 2023.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
23
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$1.3M
Net income-US$21.5M-1664.9% margin
Last declaration on 24 November 2023
Declarations23 total
174,742 shares100.0% of flowCommon StockSEC:0001209191-23-056578:0
80,968 shares0Common StockSEC:0001628280-23-001321:0
74,739 shares0Common StockSEC:0001628280-23-000421:0
60,414 shares0Common StockSEC:0001628280-23-000413:0
87,196 shares0Common StockSEC:0001628280-23-000420:0
60,414 shares0Common StockSEC:0001628280-23-000422:0
121,452 shares0Common StockSEC:0001628280-23-000419:0
60,580 shares0Common StockSEC:0001628280-23-000354:0
60,580 shares0Common StockSEC:0001628280-22-024213:0
46,489 shares0Common StockSEC:0001628280-22-024218:0
35,082 shares0Common StockSEC:0001628280-22-024221:0
35,082 shares0Common StockSEC:0001628280-22-024219:0
43,400 shares0Common StockSEC:0001628280-22-024220:0
21,054 shares0Common StockSEC:0001628280-22-024156:0
13,568 shares0Common StockSEC:0001628280-22-000412:0
21,504 shares0Common StockSEC:0001628280-22-000413:0
28,384 shares0Common StockSEC:0001628280-22-000415:0
18,715 shares0Common StockSEC:0001628280-22-000409:0
14,036 shares0Common StockSEC:0001628280-22-000411:0
19,494 shares0Common StockSEC:0001628280-22-000416:0
35,000 sharesCommon StockSEC:0001358403-16-000130:0
32,700 sharesCommon StockSEC:0001358403-16-000130:1
2,300 sharesCommon StockSEC:0001358403-16-000130:2
23 of 23 declarations
About Bellicum Pharmaceuticals, Inc
Bellicum Pharmaceuticals, Inc. (ticker BLCM) is a U.S.-based biopharmaceutical company historically listed on NASDAQ in the United States. Founded in 2004 and long headquartered in Houston, Texas, near the Texas Medical Center, the company was built around controllable cell-therapy technologies and proprietary cell-signaling platforms. Its original investment case centered on next-generation immunotherapies for cancer and selected blood-disorder indications, with an emphasis on combining anti-tumor efficacy with built-in safety control. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1358403/000156459015001868/blcm-10k_20141231.htm?utm_source=openai))
From a business-line perspective, Bellicum’s historical pipeline was organized around several proprietary platforms, notably CaspaCIDe® (a drug-activated safety switch), iMC (inducible MyD88/CD40), and the GoCAR-T® platform. These technologies were designed to improve expansion, persistence, and anti-tumor activity of engineered cells while giving physicians an added control mechanism if adverse events emerged. The best-known programs included BPX-501, aimed at complications associated with allogeneic hematopoietic stem cell transplantation, and BPX-601 and BPX-603, developed for oncology, particularly solid tumors. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-closes-20-million-series-b-financing?utm_source=openai))
Read moreShow less
In competitive terms, Bellicum operated in the highly crowded cell-therapy and immuno-oncology arena, where large pharma groups, well-funded specialty biotechs, and academic spinouts compete for clinical differentiation, intellectual property, and capital. Bellicum’s core differentiator was its controllability layer—an appealing scientific thesis, but one that typically requires long development timelines, substantial funding, and rigorous clinical execution. The company also relied on collaborations and licensing arrangements to advance its technology base, including partnerships with major cancer centers and academic institutions. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-third-quarter-2021-financial-results-and?utm_source=openai))
Recent corporate developments are critical. In March 2023, Bellicum announced it was discontinuing its Phase 1/2 GoCAR-T trials and initiating a review of strategic alternatives. In November 2023, the company entered into an asset purchase agreement with The University of Texas MD Anderson Cancer Center covering substantially all of its R&D assets; that asset sale was completed on February 21, 2024. In 2023, the company also disclosed that its shares were expected to move to OTCQX, underscoring a major contraction in the listed equity story. For investors, Bellicum should therefore be viewed less as a conventional growth-stage biotech and more as a restructuring/asset-monetization situation. ([ir.bellicum.com](https://ir.bellicum.com/news-releases/news-release-details/bellicum-discontinues-phase-12-trials-and-initiates-evaluation?utm_source=openai))
